LON:GSK - GlaxoSmithKline Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 1,582 +10.40 (+0.66 %) (As of 05/27/2019 03:01 AM ET)Previous CloseGBX 1,571.60Today's RangeGBX 1,570.60 - GBX 1,586.8052-Week RangeGBX 1,408.80 - GBX 1,648.80Volume6.29 million shsAverage Volume9.12 million shsMarket Capitalization£78.26 billionP/E Ratio20.15Dividend Yield5.85%BetaN/A ProfileAnalyst RatingsChartDividendEarningsInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Sensodyne, parodontax, Poligrip, Voltaren, Panadol, Otrivin, and Theraflu brand names. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, pods, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, and malted drinks and foods. Its primary collaboration is with 23andMe; and strategic alliance is with Merck KGaA to jointly develop and commercialize M7824. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Receive GSK News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:GSK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.gsk.com/ Phone+44-20-80475000Debt Debt-to-Equity Ratio942.07 Current Ratio0.72 Quick Ratio0.45Price-To-Earnings Trailing P/E Ratio20.15 Forward P/E Ratio0.14 P/E GrowthN/A Sales & Book Value Annual Sales£31.26 billion Price / Sales2.50 Cash FlowGBX 89.74 per share Price / Cash Flow17.63 Book ValueGBX 81.20 per share Price / Book19.48Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees95,490 Outstanding Shares4,946,990,080Market Cap£78.26 billion Next Earnings Date7/24/2019 (Estimated) OptionableOptionable GlaxoSmithKline (LON:GSK) Frequently Asked Questions What is GlaxoSmithKline's stock symbol? GlaxoSmithKline trades on the London Stock Exchange (LON) under the ticker symbol "GSK." How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline? GlaxoSmithKline announced a dividend on Wednesday, May 1st. Shareholders of record on Thursday, May 16th will be given a dividend of GBX 19 per share on Thursday, July 11th. This represents a yield of 1.22%. The ex-dividend date is Thursday, May 16th. The official announcement can be seen at this link. View GlaxoSmithKline's Dividend History. How were GlaxoSmithKline's earnings last quarter? GlaxoSmithKline plc (LON:GSK) announced its quarterly earnings data on Wednesday, April, 25th. The company reported $24.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $24.30 by $0.30. View GlaxoSmithKline's Earnings History. When is GlaxoSmithKline's next earnings date? GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for GlaxoSmithKline. What price target have analysts set for GSK? 19 brokerages have issued 12-month price targets for GlaxoSmithKline's shares. Their forecasts range from GBX 41.74 to GBX 1,900. On average, they anticipate GlaxoSmithKline's stock price to reach GBX 1,526.14 in the next year. This suggests that the stock has a possible downside of 3.5%. View Analyst Price Targets for GlaxoSmithKline. What is the consensus analysts' recommendation for GlaxoSmithKline? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline. Has GlaxoSmithKline been receiving favorable news coverage? Media coverage about GSK stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of GlaxoSmithKline's key competitors? Some companies that are related to GlaxoSmithKline include AstraZeneca (AZN), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Futura Medical (FUM) and Vita Life Sciences (VLS). What other stocks do shareholders of GlaxoSmithKline own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AstraZeneca (AZN), General Electric (GE), AT&T (T), Vodafone Group (VOD), Intel (INTC), Allergan (AGN), Bank of America (BAC), Pfizer (PFE), BP (BP) and Lloyds Banking Group (LLOY). Who are GlaxoSmithKline's key executives? GlaxoSmithKline's management team includes the folowing people: Ms. Emma N. Walmsley, CEO & Director (Age 49)Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)Mr. Simon P. Dingemans, Exec. Director (Age 55)Mr. Jack Bailey, Pres of US PharmaceuticalsMr. Iain James Mackay, CFO & Exec. Director (Age 57) How do I buy shares of GlaxoSmithKline? Shares of GSK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is GlaxoSmithKline's stock price today? One share of GSK stock can currently be purchased for approximately GBX 1,582. How big of a company is GlaxoSmithKline? GlaxoSmithKline has a market capitalization of £78.26 billion and generates £31.26 billion in revenue each year. GlaxoSmithKline employs 95,490 workers across the globe. What is GlaxoSmithKline's official website? The official website for GlaxoSmithKline is http://www.gsk.com/. How can I contact GlaxoSmithKline? GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The company can be reached via phone at +44-20-80475000. MarketBeat Community Rating for GlaxoSmithKline (LON GSK)Community Ranking: 1.9 out of 5 ()Outperform Votes: 894 (Vote Outperform)Underperform Votes: 1,450 (Vote Underperform)Total Votes: 2,344MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/27/2019 by MarketBeat.com StaffFeatured Article: Trading Strategy Methods for Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.